Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204514 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Yanping Liu und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Cross-Over Studies, Therapeutic Equivalency, Fasting, Tablets.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Liu, Y., Lü, L., Xu, M., Tao, J., Ning, Y., Shi, Y., Dong, Y., Cao, Q., Ma, J., & Qiu, Y. (2024). Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204514
Vancouver
Liu Y, Lü L, Xu M, Tao J, Ning Y, Shi Y, et al. Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204514
BibTeX
@article{Liu2024,
author = {Liu, Yanping and Lü, Lang and Xu, Man and Tao, Juanmin and Ning, Yuping and Shi, Yan and Dong, Yanfen and Cao, Qingqing and Ma, Jun and Qiu, Yan},
title = {Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204514}
}
EUVIMED